Mithra Signs LSA with Alvogen for Commercialization of Estelle® in Hong Kong and Taiwan

  • Mithra grants exclusive license to Alvogen for commercialization of its combined oral contraceptive Estelle® in Hong Kong and Taiwan
  • Agreement follows licensing deals for Estelle® with market leaders in U.S., Europe, Russia, Canada, Brazil, Japan, South Korea, Middle East and South Africa
Liege, Belgium, 6 January 2020 – 7 :30  CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it has signed an exclusive license and supply agreement with Alvogen for the commercialization of Estelle® in Hong Kong and Taiwan. Estelle® is Mithra’s novel combined oral contraceptive (COC) product candidate, containing 15 mg Estetrol (E4) and 3 mg drospirenone (DRSP).